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Abstract
Background: Both anaemia and red blood cell (RBC) transfusion are common and associated with adverse outcomes
in patients admitted to the intensive care unit (ICU). The aim of this study was to determine whether serum hepcidin
concentration, measured early after ICU admission in patients with anaemia, could identify a group in whom
intravenous (IV) iron therapy decreased the subsequent RBC transfusion requirement.
Methods: We conducted a prospective observational study nested within a multicenter randomized controlled
trial (RCT) of IV iron versus placebo. The study was conducted in the ICUs of four tertiary hospitals in Perth, Western
Australia. Critically ill patients with haemoglobin (Hb) of < 100 g/L and within 48 h of admission to the ICU were
eligible for participation after enrolment in the IRONMAN RCT. The response to IV iron therapy compared with placebo
was assessed according to tertile of hepcidin concentration.
Results: Hepcidin concentration was measured within 48 h of ICU admission in 133 patients. For patients in the lower
two tertiles of hepcidin concentration (< 53.0 μg), IV iron therapy compared with placebo was associated with a
significant decrease in RBC transfusion requirement [risk ratio 0.48 (95% CI 0.26–0.85), p = 0.013].
Conclusions: In critically ill patients with anaemia admitted to an ICU, baseline hepcidin concentration predicts
RBC transfusion requirement and is able to identify a group of patients in whom IV iron compared with placebo
is associated with a significant decrease in RBC transfusion requirement.
Trial registration: Australian New Zealand Clinical Trials Registry: ANZCTRN12612001249 Registered 26/11/2012
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Background
Anaemia is common in patients admitted to the intensive
care unit (ICU) and is associated with adverse outcomes
[1, 2]. Despite evidence to support a restrictive red blood
cell (RBC) transfusion threshold, anaemia is also the most
common indication for RBC transfusion in the ICU, itself
associated with increased morbidity and mortality [3].
In non-critically ill patients, intravenous (IV) iron
therapy is effective in promoting erythropoiesis and de-
creasing RBC transfusion requirement [4]. However, re-
cent randomized controlled trials (RCTs) of IV iron
therapy in critically ill patients have not demonstrated
benefit [5, 6]. This may be because critical illness results
in an acute inflammatory response that confounds the
interpretation of standard, clinically available measures
of iron deficiency used in these studies. By contrast, the
serum concentration of hepcidin, a key regulator of iron
metabolism, decreases in response to iron-restricted
erythropoiesis, even in the presence of inflammation [7].
Hepcidin is a small peptide secreted predominantly by
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the liver and acts by blocking duodenal iron absorption
and decreasing availability of iron stored in hepatocytes
and macrophages to red cell precursors. Although hepci-
din may be more accurate in predicting an increase in
red blood cell production in response to IV iron, pro-
spective clinical data is lacking.
The primary aim of this study was to determine
whether low serum hepcidin concentration could iden-
tify a subset of critically ill patients with anaemia in
whom IV iron therapy was effective in reducing RBC
transfusion requirement.
Methods
The study was a prospective cohort study, nested within
the IRONMAN RCT, the protocol and primary results
of which have previously been published [5, 8]. Briefly,
the IRONMAN RCT enrolled adult patients who were
within 48 h of admission to ICU, had a hemoglobin (Hb)
of less than 100 g/L, and were anticipated to require
ICU care beyond the next calendar day. Exclusion cri-
teria included suspected or confirmed severe sepsis, a
ferritin greater than 1200 ng/mL or transferrin satur-
ation greater than 50%. Participants were randomised in
a 1:1 ratio to receive either 500 mg IV ferric carboxymal-
tose or placebo and were followed up to hospital dis-
charge. Human Research Ethics Committee approval
was obtained at all sites prior to commencement, and
prospective consent was obtained from all participants
or their legal surrogates.
For this nested cohort study, blood was collected for
serum hepcidin measurement immediately following
enrolment and prior to study drug administration.
Hepcidin-25 was isolated from blood for quantitation by
liquid chromatography-quadrupole time-of-flight mass
spectrometry (LC-qTOF-MS), using a Waters Synapt
G2S (Waters, Manchester, UK) as previously described
[9, 10]. Hepcidin was isolated by solid phase extraction
following the initial addition of a synthetic human hepci-
din (13C18,
15N3) peptide internal standard (Peptides
International, Kentucky, USA) and removal of the more
abundant polypeptides by organic solvent precipitation
and centrifugation. The accurate mass measurement of
the precursor hepcidin-25 [M+5H]5+ ion was confirmed
against a hepcidin-25 standard (Peptides International,
Kentucky, USA) and further by MS/MS. Quantitation
was by reference to a human hepcidin-25 (13C18,
15N3)
calibration, prepared in human serum.
The primary objective was to determine whether hep-
cidin concentration could identify a group of critically ill
patients for whom IV iron therapy was effective in de-
creasing the risk of RBC transfusion. The secondary ob-
jective was to develop a prognostic model for RBC
transfusion quantity in patients admitted to the ICU.
Statistical analysis
Continuous variables were reported as mean (± SD) or
median and interquartile range (IQR), with between-
group differences analyzed using Student’s t test or the
Wilcoxon rank-sum test for apparently normal and
Fig. 1 Derivation of the cohort
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non-normally distributed data respectively. Categorical
variables were reported as proportion and analyzed
using the χ2 test or Fischer exact test as appropriate.
Data was censored at 60 days after enrolment for RBC
transfusion Hb concentration and vital status.
The relationship between hepcidin concentration and
response to IV iron therapy was examined using similar
methodology to a previously published RCT of IV iron
in patients with chemotherapy-induced anaemia con-
ducted by Steensma et al. [11]. Similar to this method-
ology, patients were first stratified by tertile of baseline
hepcidin concentration then combined. The incident risk
ratio for RBC transfusion was then compared between
those who were randomized to receive IV iron and those
who received placebo. The relationship between IV iron
therapy and RBC transfusion quantity across the range
of hepcidin values was further explored by locally
weighted scatterplot smoothing (LOWESS) [12]. Receiver-
operator characteristic curve analysis was not undertaken
because the IRONMAN RCT demonstrated nearly identi-
cal overall proportions of patients transfused in the two
groups.
The model to predict subsequent RBC transfusion
quantity in patients admitted to the ICU was developed
using negative binomial univariate and multivariate ana-
lyses. Variables with a p value of < 0.3 on univariate ana-
lysis were included in a multivariable analysis with
backwards selection with an alpha of 0.05. Interaction
was assessed using multivariable fractional polynomials
to account for potential non-linear relationships. Signifi-
cant interactions (p value of < 0.05) were examined
graphically, and a final model was then produced. The
relative prognostic value with and without baseline hep-
cidin concentration included was assessed using Akaike
information criterion (AIC).
Outcome data was censored at 60 days after enrolment.
A two-sided p value of 0.05 or less was considered to be
statistically significant. All analyses were conducted with
Stata Version 14 StataCorp College Station, TX77845,
USA.
Results
Baseline hepcidin levels were available for 133 (95%)
out of the 140 participants enrolled in the IRONMAN
RCT. The flow of participants is presented in Fig. 1.
The mean time from ICU admission to collection was
29 h [standard deviation (SD) 13], and median hepci-
din concentration was 34.9 μg/L [interquartile range
(IQR) 17.3–69.2, range 0–163.5]. The baseline charac-
teristics of the population are provided in Table 1.
There was no significant correlation between hepcidin
concentration and baseline C reactive protein or iron
indices (see Additional file 1).
Hepcidin and prediction of response to IV iron
Of the 88 patients in the lower two tertiles of hepcidin
concentration (0 to 53.0 μg/L), 44 received IV iron therapy
and 44 received placebo. In patients with a low hepcidin
concentration (≤ 53.0 μg/L), the relative risk (RR) of RBC
transfusion associated with IV iron was 0.48 (95% CI
0.26–0.85), p = 0.013. In patients with a high hepcidin
level (> 53.0 μg/L), there was no significant association be-
tween IV iron therapy and risk of RBC transfusion, RR
1.33 (95% CI 0.57–3.08), p = 0.518. The association be-
tween IV iron therapy and RBC transfusion by tertile of
hepcidin concentration is provided in Table 2. The associ-
ation between hepcidin concentration and RBC transfu-
sion quantity in patients who received IV iron compared
with placebo is represented by the LOWESS plot in Fig. 2.
Table 1 Baseline characteristics
Characteristic* Outcome (n = 133)
Age—years 62 (41–73)
Male gender—no. (%) 91 (68)
ICU admission source—no (%)
Emergency department 24 (18)
Hospital ward 8 (6)
Operating theater 97 (73)
Other hospital 4 (3)
ICU admission type—no (%)
Medical 17 (13)




APACHE II score 12 (9–17)
SOFA score 6 (4–9)
Prior RBC transfusion—no (%) 30 (23)
Haemoglobin—g/L 88 (81–94)
Mean corpuscular volume—fL 91 (88–94)




Transferrin saturation—% 9 (6–16)
Soluble transferrin receptor—mg/L 1.81 (1.28–2.44)
Hepcidin—μg/mL 34.9 (17.3–69.2)
Tertile 1—(0–20.08) 10.6 (4.2–15.6)
Tertile 2—(20.09–53.00) 34.9 (27.1–48.5)
Tertile 3—(53.01–163.46) 81.2 (69.2–97.9)
ICU intensive care unit, APACHE acute physiology and chronic health evaluation,
SOFA sequential organ failure assessment, RBC red blood cell
*Median and interquartile range (IQR) unless otherwise reported
+ng/ml has a conversion factor of 1 to the standard international units mcg/ml
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IV iron therapy compared with placebo was not asso-
ciated with a significant increase in Hb for those in the
lower two tertiles of hepcidin values [mean increase Hb
3 g/L (95% CI − 3–10), p = 0.361]. There was no signifi-
cant correlation between hepcidin and concurrent Hb,
ferritin, transferrin saturation, soluble transferrin recep-
tor or C reactive protein. There was also no significant
difference in iron, transferrin saturation, ferritin or
transferrin receptor levels associated with lower versus
higher hepcidin tertile (see Additional file 1).
Predicting RBC transfusion quantity
The complete list of variables assessed on univariate
analysis and those added to the initial multivariable
model is provided in Additional file 1. ICU admission
related to trauma, baseline Hb < 80 g/L, lower transfer-
rin saturation and lower hepcidin concentration were
found to predict increased risk of RBC transfusion and
were retained in the final multivariable model. There
was a significant interaction between Hb and hepcidin
concentrations in predicting the risk of RBC transfusion
(likelihood ratio test for significance of interaction p =
0.0462), see Additional file 1: Figure S1. For patients
with a Hb ≥ 80 g/L, each 10 μg/mL increase in hepcidin
concentration was associated with a risk ratio of RBC
transfusion of 1.09 (95% CI 1.01–1.18, p = 0.034). How-
ever, for patients with a Hb < 80 g/L, there was no sig-
nificant association between hepcidin concentration and
risk of RBC transfusion [RR 0.95 (95% CI 0.84–1.07), p
= 0.387]. The variables included in the final model are
Table 2 Hepcidin and risk of RBC transfusion with IV iron therapy
Variable IV iron Placebo Risk ratio (95% CI) p value
Hepcidin ≤ 53.0 μg/L
Number RBC units/patients 38/44 80/44
Median RBC units (IQR) 1 (0–2) 1 (0–3) 0.48 (0.26–0.85) 0.013
Hepcidin 1st tertile (0–20.1 μg/L)
Number RBC units/number patients 23/22 35/21
Median RBC units (IQR) 1 (0–2) 0 (0–2) 0.63 (0.26–1.50) 0.293
Hepcidin 2nd tertile (20.1–53.0 μg/L)
Number RBC units/number patients 15/22 45/23
Median RBC units (IQR) 0 (0–1) 1 (0–3) 0.35 (0.16–0.77) 0.009
Hepcidin 3rd tertile (> 53.0 μg/L)
Number RBC units/number patients 43/22 34/23
Median RBC units (IQR) 1 (0–3) 1 (0–3) 1.33 (0.57–3.08) 0.518
RBC red blood cell, IQR interquartile range
Fig. 2 Association between hepcidin concentration and Red Blood Cell units transfused for patients receiving IV iron and placebo
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provided in Table 3. AIC with hepcidin in the model was
415.14 versus 468.16 with hepcidin removed.
Discussion
We found that serum hepcidin concentration identified a
subset of anaemic, critically ill patients in whom IV iron
therapy was effective in reducing RBC transfusion require-
ment. These findings are important when considering the
dose-response relationship between increasing RBC trans-
fusion quantity and worse clinical outcomes and also due
to the scarcity and cost of RBC transfusion. In addition to
predicting the effectiveness of IV iron in critically ill pa-
tients, we also found that hepcidin concentration was an
independent predictor of RBC transfusion requirement
but that the association was modified by Hb levels.
Although Lasocki et al. have described low hepcidin
concentrations in some critically ill patients with anaemia,
there is limited data exploring whether hepcidin can be
used to guide treatment decisions [7]. Steensma et al.
found that hepcidin concentration could predict response
to IV iron therapy in patients with chemotherapy-induced
anaemia [11]. In our study, the median C reactive protein
was 110 mg/L but did not correlate with hepcidin concen-
tration, suggesting that even in the presence of inflamma-
tion, measurement of hepcidin is useful in identifying
critically ill patients in whom IV iron therapy is likely to
reduce RBC transfusion requirement [13]. Our findings
also support further investigation into the role of hepcidin
antagonists in patients with elevated hepcidin [14].
Hepcidin synthesis is finely regulated and induced by both
inflammation and iron overload [15]. Hepcidin levels have
been shown to be the predominant predictor of erythrocyte
iron incorporation in African children with anaemia [16].
Amongst adult patients admitted to the ICU, Tacke et al.
have demonstrated an association between markers of in-
creased iron availability and mortality [17]. It is plausible
that using hepcidin concentration to target IV iron therapy
in critically ill patients can also reduce the potential risk of
initiating or exacerbating infection associated with both ex-
cessively high free iron levels and iron deficiency.
Accurate prediction of RBC transfusion quantity could
provide an additional method to target IV iron therapy in
critically ill patients. In the IRONMAN RCT, subgroup
analysis did not suggest a differential effect of IV iron re-
lated to transferrin saturation or ferritin concentration [5].
Building on these findings, the current study found no sig-
nificant difference in iron indices based on hepcidin tertile
or correlation between iron indices and hepcidin. Although
iron-restricted erythropoiesis is not present in all critical
patients who require RBC transfusion, our study found
that hepcidin was an independent predictor of subsequent
transfusion. Although our model requires validation, a
metric of observed versus predicted RBC transfusion may
also be useful as a quality metric.
Future studies must also address the substantial vari-
ation that currently exists in hepcidin assays and refer-
ence ranges that makes comparison between studies
difficult [14]. A reliable point of care hepcidin test is ne-
cessary to provide results in a clinically useful timeframe.
The ongoing HEPCIDANE RCT (NCT02276690) of
hepcidin-guided management of anaemia in critically ill
patients will address some of these issues.
Limitations
Our study was limited to patients with an Hb < 100 g/L
and did not enroll patients with sepsis. Whether hepcidin
measurement is useful in these patients remains uncertain.
Although soluble transferrin receptor levels were not
found not to be predictive of RBC transfusion require-
ment in our study, other assays with potential diagnostic
benefit including zinc protophoryn were not assessed.
However, given the central role of hepcidin in iron metab-
olism, it is unlikely that other assays provide superior
diagnostic utility. The relatively small number of partici-
pants precluded the use of methods to reduce the risk of
over-fitting of the statistical models, and larger studies are
required to validate the findings. Finally, the current study
only assessed the use of hepcidin at a single point in time.
Greater understanding is required of how hepcidin levels
change over time including the effect interventions such
as RBC transfusion and IV iron therapy.
Conclusion
In patients with anaemia admitted to the ICU, hepcidin
measurement can identify a group of patients in whom
IV iron therapy decreases RBC transfusion requirement.
Table 3 Final multivariate model—independent predictors of RBC transfusion
Characteristic (n = 133) Coefficient (95% CI) Risk ratio (95% CI) p value
ICU admission type—trauma vs non trauma 0.833 (0.382–1.285) 2.30 (1.46–3.61) < 0.001
Haemoglobin > 80 g/L*—yes vs no − 0.99 (− 1.493 to − 0.493) 0.37 (0.22–0.61) < 0.001
Transferrin saturation—per 10% increase 0.237 (0.082–0.391) 1.27 (1.09–1.48) 0.003
Hepcidin—per 10 μg/ml increase 0.086 (0.030–0.142) 1.09 (1.03–1.15) 0.002
CI confidence interval, ICU intensive care unit. Constant for model 0.088 (95% CI − 0.398–0.575)
*Likelihood ratio test for significance of interaction between haemoglobin as a continuous variable and hepcidin concentration in predicting the risk of RBC
transfusion p = 0.0462. For patients with a haemoglobin < 80 g/L, there was no significant association between hepcidin concentration and risk of RBC transfusion
[RR 0.95 (95% CI 0.84–1.07), p = 0.387]
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Additional file
Additional file 1: Figure S1. Relationship between hepcidin concentration
and RBC transfusion, moderated by haemoglobin concentration. Hb
Haemoglobin, RBC red blood cell. Table S1. Iron indices according to
hepcidin levels. Table S2. Univariate analysis of variables associated
with risk of RBC transfusion. CI confidence interval, ICU intensive care
unit, APACHE acute physiology and chronic health evaluation, SOFA
sequential organ failure assessment. Variables in bold added to the initial
multivariable model. (DOCX 108 kb)
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